Cabozantinib Improves Survival in Renal Cell Carcinoma

Cabozantinib (Cabometyx) reduced the risk of death by 34% compared with everolimus (Afinitor) in patients with previously treated advanced renal cell carcinoma (RCC), according to updated data from the phase 3 METEOR trial presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO).¹

The results, which were simultaneously published in The Lancet Oncology,² showed a 4.9-month median overall survival (OS) benefit with cabozantinib. The risk of disease progression was reduced by 49% with the multi kinase inhibitor versus everolimus. Based on the METEOR trial’s results, the FDA approved cabozantinib in April 2016 for patients with advanced RCC who had prior antiangiogenic therapy.³

“In the phase 3 METEOR trial, treatment with cabozantinib was associated with a significant improvement in overall survival, as well as progression-free survival and objective response rate compared with everolimus in patients with advanced renal cell carcinoma. Cabozantinib is a new standard for patients with advanced RCC after prior antiangiogenic therapy,” lead author Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, said when presenting the data at ASCO.

The complete article can be accessed here: http://bit.ly/29Qpg9I.Jason M. Broderick is associate director, Digital Editorial, OncLive.com.